Adage Capital Partners
RVNC

Adage Capital Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Adage Capital Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,653,689
Closed -$5.03M – 983
2024
Q4 		$5.03M Buy
1,653,689
+603,689
+57% +$2.63M 0.01% 717
2024
Q3 		$5.45M Buy
+1,050,000
New +$5.22M 0.01% 707
2017
Q3 		– Sell
-12,183
Closed -$322K – 763
2017
Q2 		$322K Sell
12,183
-337,817
-97% -$7.53M ﹤0.01% 698
2017
Q1 		$7.28M Hold
350,000
– – 0.02% 578
2016
Q4 		$7.25M Hold
350,000
– – 0.02% 567
2016
Q3 		$5.67M Sell
350,000
-25,000
-7% -$363K 0.02% 601
2016
Q2 		$5.1M Hold
375,000
– – 0.01% 588
2016
Q1 		$6.55M Hold
375,000
– – 0.02% 579
2015
Q4 		$12.8M Buy
375,000
+199,227
+113% +$6.91M 0.03% 484
2015
Q3 		$5.23M Buy
+175,773
New +$5.34M 0.01% 611

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Adage Capital Partners's RVNC Position: Q1 2025 in Review

Adage Capital Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,653,689 shares — an estimated $5.03M sold.

Adage Capital Partners first reported a position in RVNC in Q3 2015 and held it in 10 quarters. The position peaked at $12.8M in Q4 2015. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Adage Capital Partners reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 1,653,689 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $5.03M.
  • Adage Capital Partners first reported a position in Revance Therapeutics, Inc. in Q3 2015 and held it in 10 quarters.
  • Adage Capital Partners's Revance Therapeutics, Inc. position peaked at $12.8M in Q4 2015.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.